Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an update.
Atomo Diagnostics announced the national expansion of the CONNECT Programme, which will provide free HIV self-tests through vending machines across Australia, funded by the Federal Government. This initiative, supported by an initial order from Thorne Harbour Health, represents a significant advancement in public health efforts to increase access to HIV self-testing. Additionally, Atomo has launched its HIV Self-Test in New Zealand through Chemist Warehouse, marking its entry into the country’s largest retail pharmacy chain. These developments highlight Atomo’s growing influence in the HIV testing market and its commitment to expanding international market access.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics is an Australian medical device company that supplies unique, integrated rapid diagnostic test devices to the global market. Their patented devices simplify testing procedures and improve reliability for point-of-care and at-home testing applications. The company has commercialized products for infectious diseases such as HIV and COVID-19, as well as for early pregnancy detection.
YTD Price Performance: -15.79%
Average Trading Volume: 260,648
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$10.23M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.